Payment overview · 2025
General Payments
$304.53
13 reported records · 6 companies
Healthcare provider profile · identity verified
Paul Diehl, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WEST HILLS, CA · NPI 1336215607
Verified facts
What the public records show
CMS Open Payments records show Paul Diehl, M.D. received $304.53 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 58.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.81 | 58.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.31 | 13.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.59 | 9.1% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $23.68 | 7.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.40 | 6.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.74 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $304.53 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $176.81 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 46 |
| Alprazolam | Alprazolam | 160 | 31 |
| Gabapentin | Gabapentin | 153 | 36 |
| Losartan Potassium | Losartan Potassium | 150 | 38 |
| Lisinopril | Lisinopril | 147 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 24 |
| Temazepam | Temazepam | 136 | 17 |
| Metformin Hcl | Metformin Hcl | 132 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 29 |
| Trazodone Hcl | Trazodone Hcl | 94 | 17 |
| Sertraline Hcl | Sertraline Hcl | 92 | 19 |
| Eliquis | Apixaban | 90 | 15 |
| Lorazepam | Lorazepam | 88 | 19 |
| Furosemide | Furosemide | 87 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 86 | 15 |
| Omeprazole | Omeprazole | 83 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 23 |
| Tramadol Hcl | Tramadol Hcl | 78 | 16 |
| Simvastatin | Simvastatin | 77 | 20 |
| Donepezil Hcl | Donepezil Hcl | 71 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 12 |
| Allopurinol | Allopurinol | 66 | 14 |
| Carvedilol | Carvedilol | 66 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 16 |
| Famotidine | Famotidine | 58 | 16 |
| Azithromycin | Azithromycin | 57 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 15 |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 53 | 14 |
| Potassium Chloride | Potassium Chloride | 53 | 22 |
| Spironolactone | Spironolactone | 51 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Edarbi | Azilsartan Medoxomil | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Digoxin | Digoxin | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Carisoprodol | Carisoprodol | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Meloxicam | Meloxicam | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Roflumilast | Roflumilast | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $304.53 · 13 records | ABBVIE INC. | JATENZO, LEQVIO, LOREEV XR, Ozempic, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error